Phospho-ALK (Tyr1282/1283) Antibody (Rabbit mAb) [K9K20]

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 IP1:100

Application
WB, IP

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
176 kDa 80 kDa (NPM-ALK), 220 kDa (ALK)
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Phospho-ALK (Tyr1282/1283) Antibody (Rabbit mAb) [K9K20] detects endogenous levels of ALK protein only when phosphorylated at Tyr1282/1283.

Clone
K9K20

Synonym(s)
ALK; ALK receptor tyrosine kinase; ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; anaplastic lymphoma receptor tyrosine kinase; CD246; CD246 antigen; mutant anaplastic lymphoma kinase; NBLST3

Background
Phospho-ALK (Tyr1282/1283) denotes the activated state of the anaplastic lymphoma kinase receptor in which two tyrosines within its activation loop are phosphorylated, a modification that is equivalent to Tyr342/343 in the oncogenic NPM–ALK fusion and marks catalytically engaged kinase capable of transmitting proliferative and survival signals. The ALK kinase domain follows the typical receptor tyrosine kinase fold with an activation loop containing Tyr1282 and Tyr1283, and phosphoproteomic mapping has identified these residues as key activation-loop phosphosites along with additional regulatory sites elsewhere in the kinase, defining a phospho-pattern that distinguishes inactive from signaling-competent ALK. Ligand binding or fusion-driven dimerization leads to ALK autophosphorylation within this activation loop, with phosphorylation of Tyr1282/1283 stabilizing the active conformation and creating docking surfaces for downstream effectors; antibodies that specifically recognize ALK only when phosphorylated at Tyr1282/1283 have shown that this state is present in select carcinoma cell lines and tumors and corresponds to strong downstream pathway activation. Once phosphorylated at Tyr1282/1283, ALK transduces signals through multiple cascades, prominently the Ras–ERK/MAPK axis, PI3K–Akt pathway and JAK–STAT signaling, leading to induction of genes that support cell-cycle progression, anti-apoptotic programs and invasive behavior. In neuroblastoma and other ALK-driven contexts, activated ALK robustly phosphorylates STAT3 on Tyr705, linking the Tyr1282/1283 activation-loop state to STAT3-dependent transcriptional programs that promote growth and resistance to stress. In NPM–ALK-positive anaplastic large-cell lymphoma and EML4–ALK-positive non-small cell lung cancer, constitutive activation-loop phosphorylation is sustained by fusion-mediated oligomerization, yielding phospho-ALK Tyr1282/1283 as a stable oncogenic signal that drives PLCγ, IRS‑1, Shc and PI3K activation and underpins the mitogenic and survival phenotypes of these fusion proteins. Mutational analysis of neighboring residues, such as ALK Y1278S, reveals that changes in the activation-loop region can produce ligand-independent phosphorylation of ALK itself and its downstream targets, indicating that phosphorylation at Tyr1282/1283 integrates with local sequence features to tune basal and induced kinase activity. Across tumor types, phospho-ALK Tyr1282/1283 serves as a functional biomarker of ALK pathway engagement: its detection correlates with responsiveness to ALK tyrosine kinase inhibitors and helps stratify tumors with ALK alterations in pan-cancer analyses, supporting its use to monitor target inhibition and emergent resistance in precision oncology.

Background

Phospho-ALK (Tyr1282/1283) denotes the activated state of the anaplastic lymphoma kinase receptor in which two tyrosines within its activation loop are phosphorylated, a modification that is equivalent to Tyr342/343 in the oncogenic NPM–ALK fusion and marks catalytically engaged kinase capable of transmitting proliferative and survival signals. The ALK kinase domain follows the typical receptor tyrosine kinase fold with an activation loop containing Tyr1282 and Tyr1283, and phosphoproteomic mapping has identified these residues as key activation-loop phosphosites along with additional regulatory sites elsewhere in the kinase, defining a phospho-pattern that distinguishes inactive from signaling-competent ALK. Ligand binding or fusion-driven dimerization leads to ALK autophosphorylation within this activation loop, with phosphorylation of Tyr1282/1283 stabilizing the active conformation and creating docking surfaces for downstream effectors; antibodies that specifically recognize ALK only when phosphorylated at Tyr1282/1283 have shown that this state is present in select carcinoma cell lines and tumors and corresponds to strong downstream pathway activation. Once phosphorylated at Tyr1282/1283, ALK transduces signals through multiple cascades, prominently the Ras–ERK/MAPK axis, PI3K–Akt pathway and JAK–STAT signaling, leading to induction of genes that support cell-cycle progression, anti-apoptotic programs and invasive behavior. In neuroblastoma and other ALK-driven contexts, activated ALK robustly phosphorylates STAT3 on Tyr705, linking the Tyr1282/1283 activation-loop state to STAT3-dependent transcriptional programs that promote growth and resistance to stress. In NPM–ALK-positive anaplastic large-cell lymphoma and EML4–ALK-positive non-small cell lung cancer, constitutive activation-loop phosphorylation is sustained by fusion-mediated oligomerization, yielding phospho-ALK Tyr1282/1283 as a stable oncogenic signal that drives PLCγ, IRS‑1, Shc and PI3K activation and underpins the mitogenic and survival phenotypes of these fusion proteins. Mutational analysis of neighboring residues, such as ALK Y1278S, reveals that changes in the activation-loop region can produce ligand-independent phosphorylation of ALK itself and its downstream targets, indicating that phosphorylation at Tyr1282/1283 integrates with local sequence features to tune basal and induced kinase activity. Across tumor types, phospho-ALK Tyr1282/1283 serves as a functional biomarker of ALK pathway engagement: its detection correlates with responsiveness to ALK tyrosine kinase inhibitors and helps stratify tumors with ALK alterations in pan-cancer analyses, supporting its use to monitor target inhibition and emergent resistance in precision oncology.

References
https://pubmed.ncbi.nlm.nih.gov/29084134/ https://pubmed.ncbi.nlm.nih.gov/23889739/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%